

Suven Life Sciences Secures Product Patents In Mexico & NZ

08 August 2018 | News

The granted claims of the patents include the class of selective H3 and 5-HT4 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders.



Suven Life Sciences has announced grant of one product patent from Mexico and one product patent from New Zealand corresponding to the New Chemical Entities or the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2030 and 2036 respectively.

The granted claims of the patents include the class of selective H3 and 5-HT4 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia and sleep disorders like Narcolepsy etc.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally" says Venkat Jasti, CEO of Suven.